<DOC>
	<DOCNO>NCT00224445</DOCNO>
	<brief_summary>To determine safety efficacy simple , once-daily antiretroviral ( ARV ) regimen consist fixed-dose combination tablet contain Truvada combine atazanavir boosted ritonavir treatment naive patient .</brief_summary>
	<brief_title>Boosted Atazanavir Truvada Given Once-Daily - BATON Study</brief_title>
	<detailed_description>To determine safety efficacy ( viral load suppression cluster differentiation 4 [ CD4 ] change ) simple , once-daily ( QD ) antiretroviral ( ARV ) regimen consist fixed-dose combination tablet contain Truvada combine protease inhibitor atazanavir ( ATV ) boost ritonavir ( ATV/r ) . To evaluate fasting glucose , insulin , C peptide lipid panel ( total cholesterol , high low density lipoprotein cholesterol ( HDL , LDL ) , serum triglyceride ) subject receive Truvada boost atazanavir . To evaluate adherence QD ARV regimen Truvada boost atazanavir . To evaluate steady-state plasma pharmacokinetics ( PK ) Truvada atazanavir study subject receive Truvada boost atazanavir .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Adult ( great equal 18 year ) male nonpregnant female HIV 1 infected subject regardless race ethnicity . Antiretroviral treatmentna√Øve . Plasma HIV 1 RNA great 1000 copies/mL ( Roche Amplicor HIV 1 Monitor Test Version 1.5 Ultrasensitive method , reflex Standard result great 75,000 dilution result great 750,000 ) . There CD4 criterion study inclusion . Adequate renal function define calculated creatinine clearance ( CLCr ) great equal 50 mL/min accord CockcroftGault formula : Male : ( 140 age year ) x ( wt kg ) divide 72 x ( serum creatinine mg/dL ) = CLCr ( mL/min . Female : ( 140 age year ) x ( wt kg ) divide 72 x ( serum creatinine mg/dL ) x 0.85 = CLCr ( mL/min ) . Negative serum pregnancy test ( female childbearing potential ) . Males female ( childbearing potential , i.e . le 2 year postmenopausal ) must agree avoid pregnancy sexual abstinence , utilization highly effective method birth control throughout study period 30 day follow discontinuation study drug . Life expectancy great equal 1 year . Subjects available follow period least 48 week . The ability understand sign write informed consent form , must obtain prior initiation study procedure . Prior antiretroviral treatment . Screening ALT great 5 x upper limit normal range ( ULN ) . Proven suspect acute hepatitis 30 day prior study entry . Subjects chronic hepatitis eligible provide liver transaminase ( ALT ) less 5 x ULN . A new AIDS defining condition diagnose ( exception CD4 criterion ) within 30 day baseline . Previous therapy agent systemic myelosuppressive , pancreatoxic , hepatotoxic cytotoxic potential within 3 month study start expect need therapy time enrollment . Presence cardiomyopathy . Heart rate le 40 bpm . Clinical symptom potentially related heart block ( syncope , palpitation , unexplained dizziness ) Known conduction disease . Third degree heart block . Clinically significant laboratory value would preclude prescribe antiretroviral therapy , opinion investigator . Receiving ongoing therapy follow ( administration follow medication must discontinue least 30 day prior Baseline visit duration study period ) : Nephrotoxic agent ( aminoglycoside antibiotic , amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , agent significant nephrotoxic potential ) : Adefovir dipivoxil Probenecid Systemic chemotherapeutic agent ( i.e. , cancer treatment medication ) Systemic corticosteroid Interleukin 2 ( IL 2 ) Investigational agent ( except upon approval Gilead ) . Drugs contraindicate atazanavir and/or ritonavir include : midazolam triazolam ergot alkaloid pimozide protonpump inhibitor H2 blocker lovastatin simvastatin diltiazem amiodarone bepridil flecainide propafenone quinidine St. John 's Wort rifampin irinotecan Pregnant lactating subject . Evidence gastrointestinal malabsorption syndrome chronic nausea vomiting may confer inability receive orally administer medication . Current alcohol substance abuse judge investigator potentially interfere subject adherence . Malignancy cutaneous Kaposi 's sarcoma ( KS ) basal cell carcinoma . Subjects biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline anticipate require systemic therapy study . Active , serious infection ( HIV 1 infection ) require parenteral antimicrobial therapy within 15 day prior screen . Prior history significant renal bone disease . Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dose requirement . Current imprisonment involuntary incarceration medical facility psychiatric physical ( e.g. , infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>HIV-1</keyword>
</DOC>